Medicine recalls
|
| |
| Canada: Recall: Sandoz Irbesartan HCT Tablet |
| |
Health Canada announces that Sandoz Canada Incorporated is recalling 4 lots of Sandoz Irbesartan HCT Tablet (irbesartan 300mg/hydrochlorothiazide 12.5mg) (lot number: HY7383, JA4033, JA4034 and JE2529) from retailers due to presence of impurity 5-(4-(azidomethyl)-[1,1-biphenyl]-2-yl)-1H-tetrazole above the acceptable concentration limit in the affected lots.
Please refer to the following website in Health Canada for details:
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/../74779r-eng.php
In Hong Kong, Irbesartan HCT Sandoz Tab 300mg/12.5mg (HK-61534) is a pharmaceutical product registered by Novartis Pharmaceuticals (HK) Limited (Novartis), and is a prescription-only medicine. As confirmed with Novartis, the affected lots have not been imported into Hong Kong.
Ends/Friday, Jan 15, 2021
Issued at HKT 15:00
|
| |
